NetworkNewsBreaks – Earth Science Tech, Inc. (ET
Post# of 333
(Total Views: 209)
Posted On: 06/07/2018 5:26:19 PM
NetworkNewsBreaks – Earth Science Tech, Inc. (ETST) Provides Update on CBD Formula Patents, Medical Device Progress
Earth Science Tech (OTC: ETST), an innovative biotech company focused on the cannabidiol (“CBD”), nutraceutical and pharmaceutical fields, this morning provided an update regarding its ongoing CBD formula patents and medical device progress. Per the update, the prototyping of three CBD formula patents, which the company received a grant from the Government of Quebec to develop, has begun. The initial batch will be tested by the team and in vitro testing is expected to begin in summer 2019 to demonstrate the superior antioxidant activities and improved anti-proliferative effects on breast cancer cells. The third product is a superfood edible that is anticipated to be ready for Q4 of 2018. In addition, the company reported that it is currently working with Accélération, Design et Innovation Inc. regarding the final packaging of its MSN-2 medical device in preparation of its upcoming launch. “The official launch of this medical device is a little like giving birth. It will be unique in the marketplace and we are branding this device globally. The commercial name will be announced soon, as we are in the process of trademark protection for the logo and name. We will create a strong demand for this medical device by showing the world its powerful capacity to diminish the prevalence of chlamydia and other Sexually Transmitted Infections,” Earth Science Tech CEO and Chief Science Officer Dr. Michel Aubé stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Earth Science Tech (OTC: ETST), an innovative biotech company focused on the cannabidiol (“CBD”), nutraceutical and pharmaceutical fields, this morning provided an update regarding its ongoing CBD formula patents and medical device progress. Per the update, the prototyping of three CBD formula patents, which the company received a grant from the Government of Quebec to develop, has begun. The initial batch will be tested by the team and in vitro testing is expected to begin in summer 2019 to demonstrate the superior antioxidant activities and improved anti-proliferative effects on breast cancer cells. The third product is a superfood edible that is anticipated to be ready for Q4 of 2018. In addition, the company reported that it is currently working with Accélération, Design et Innovation Inc. regarding the final packaging of its MSN-2 medical device in preparation of its upcoming launch. “The official launch of this medical device is a little like giving birth. It will be unique in the marketplace and we are branding this device globally. The commercial name will be announced soon, as we are in the process of trademark protection for the logo and name. We will create a strong demand for this medical device by showing the world its powerful capacity to diminish the prevalence of chlamydia and other Sexually Transmitted Infections,” Earth Science Tech CEO and Chief Science Officer Dr. Michel Aubé stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Earth Science Tech, Inc. (ETST) Stock Research Links
Scroll down for more posts ▼